01 Expanding Availability of Biosimilar Short-Acting Insulin The development and commercialization of biosimilar short-acting insulin is emerging as an important trend in the market as healthcare providers and patients increasingly seek affordable alternatives to established insulin products. Biosimilar insulin can increase competition among manufacturers, expand treatment options, and potentially reduce the cost burden associated with diabetes management. This trend is particularly important in markets where insulin affordability and access remain major concerns. Manufacturers are also investing in regulatory approvals and commercial launches to strengthen their presence in the insulin market, while healthcare systems are increasingly considering biosimilars as part of cost-effective treatment strategies. The expansion of biosimilar options is expected to support broader access to short-acting insulin and intensify competition among established and emerging pharmaceutical companies. The FDA has noted that biosimilar approvals can increase medication options and potentially lower healthcare costs. In February 2025, the U.S. FDA approved Merilog (insulin aspart-szjj), the first rapid-acting insulin biosimilar approved in the U.S., as a biosimilar to NovoLog (insulin aspart) for improving glycemic control in adults and pediatric patients with diabetes.
02 Integration of Smart Technology With Insulin Delivery The integration of smart technology, connected insulin pens, continuous glucose monitoring (CGM), and digital diabetes applications is changing how patients administer and monitor short-acting insulin. Connected delivery devices can record insulin doses, injection timing, and other treatment information, allowing patients and healthcare professionals to better understand insulin use alongside glucose readings. These technologies can help reduce missed or repeated doses, support treatment adherence, and enable more personalized diabetes management. The growing connection between insulin delivery devices and digital health platforms is also supporting a shift toward data-driven diabetes care, where treatment decisions can be informed by continuously collected patient information. As digital diabetes ecosystems become more sophisticated, pharmaceutical and medical device companies are increasingly focusing on solutions that combine insulin delivery with monitoring and data management capabilities. In 2026, Novo Nordisk's NovoPen 6 and NovoPen Echo Plus continue to provide connected insulin delivery, automatically recording the date, time, and dose of each injection and allowing insulin data to be transferred to compatible diabetes applications alongside glucose information.
01 Government Initiatives and Improved Insulin Accessibility Support Market Expansion Government initiatives aimed at preventing diabetes, improving treatment access, and reducing the financial burden of insulin therapy are supporting the growth of the short-acting insulin market. Public healthcare programs, insurance coverage, pricing reforms, and diabetes management initiatives are helping more patients obtain essential insulin treatments. This is particularly important because people with Type 1 diabetes require insulin for survival, while many patients with Type 2 diabetes also require insulin as the disease progresses. Governments are increasingly focusing on affordable diabetes care as the global prevalence of diabetes continues to rise. Expanded reimbursement programs and policies designed to improve insulin affordability can increase treatment access and support demand for short-acting insulin products.
01 High Insulin Prices and Treatment Costs Limit Patient Access The high cost of insulin therapy remains a significant restraint for the short-acting insulin market, particularly for patients who require regular or lifelong treatment. Although short-acting insulin is essential for controlling blood glucose levels around meals, the overall cost of insulin products can place a considerable financial burden on patients, especially those without adequate insurance coverage. The complexity of insulin manufacturing, strict regulatory requirements, limited competition in some markets, and costs associated with research, production, distribution, and healthcare services can contribute to elevated prices. High out-of-pocket expenses may also encourage patients to delay prescriptions, reduce doses, or switch to less expensive treatment options, creating barriers to consistent insulin use.
01 Advances in Biosimilar Insulin Development Create New Growth Opportunities The development of biosimilar and interchangeable short-acting insulin products presents a significant opportunity for market expansion by increasing competition and improving affordability. Traditional insulin markets have been dominated by a limited number of major pharmaceutical companies, creating opportunities for new manufacturers to enter as patents expire and regulatory pathways become clearer. Advances in biotechnology, manufacturing processes, regulatory frameworks, and clinical development are making it increasingly feasible for pharmaceutical companies to develop alternative insulin products. Greater availability of biosimilar short-acting insulin could also improve access in emerging markets where treatment affordability remains a major concern.
01 Complex Manufacturing and Regulatory Requirements Restrict New Market Entrants The development of short-acting insulin presents significant challenges because insulin is a complex biological product requiring advanced manufacturing capabilities, extensive quality controls, and rigorous regulatory evaluation. New manufacturers must invest heavily in research, manufacturing infrastructure, clinical development, regulatory compliance, and distribution before bringing competing products to market. These requirements can make it difficult for smaller pharmaceutical companies to compete with established manufacturers that already possess large-scale production facilities, extensive supply networks, strong brands, and regulatory expertise. In addition, maintaining consistent product quality and ensuring reliable cold-chain distribution adds further complexity, particularly when companies seek to expand into developing and geographically diverse markets.
April 2026 Eli Lilly and Company strengthened its diabetes care business by expanding access to rapid-acting insulin therapies through enhanced manufacturing capacity and patient support initiatives across key global markets.
February 2026 Sanofi expanded its insulin portfolio by introducing enhanced delivery options and digital health integrations for short-acting insulin therapies, supporting personalized diabetes management.
September 2025 Biocon Biologics strengthened its diabetes portfolio by expanding the commercialization of insulin products and increasing manufacturing capabilities to improve the global supply of affordable insulin therapies.
May 2025 Wockhardt strengthened its insulin business by advancing the development and commercialization of rapid-acting insulin formulations designed to enhance treatment accessibility and support effective diabetes management.